^
CANCER:

Rectal Cancer





Show legend
Group by Gene:
Include preclinical:

bevacizumab
0
VEGF-A inhibitor
bevacizumab-maly
bevacizumab-adcd
bevacizumab-awwb
1
HER2-targeted antibody-drug conjugate, Topoisomerase I inhibitor
fam-trastuzumab deruxtecan-nxki
2
EGFR inhibitor
panitumumab
cetuximab
3
Thymidylate synthase inhibitor
capecitabine
5-fluorouracil
panitumumab + adagrasib
4
KRAS G12C inhibitor, EGFR inhibitor
cetuximab + adagrasib
panitumumab + sotorasib
cetuximab + sotorasib
5
VEGFR inhibitor
fruquintinib
6
Thymidine phosphorylase inhibitor
trifluridine / tipiracil
7
VEGFR-2 inhibitor
ramucirumab
8
Multi-tyrosine kinase inhibitor
regorafenib
9
HER2 inhibitor
trastuzumab + tucatinib
10
Topoisomerase I inhibitor
irinotecan
11
HER2 inhibitor, HER2 dimerization inhibitor
trastuzumab + pertuzumab
PD1 inhibitor
nivolumab
12
PD1 inhibitor
sintilimab
pembrolizumab
dostarlimab-gxly
13
PD1 inhibitor, CTLA4 inhibitor
nivolumab + ipilimumab
14
TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor
larotrectinib
15
XPO1 inhibitor
selinexor
16
RET inhibitor
selpercatinib
17
CTLA4 inhibitor
ipilimumab
FOLFIRI
FOLFIRINOX
FOLFOX
CAPOX
18
Chemotherapy
mFOLFOX6
mFOLFOX7
IROX
FOLFIRINOX + mFOLFOX6
SOXIRI
FOLFOXIRI
19
cRAF inhibitor, BRAF inhibitor, EGFR inhibitor
cetuximab + encorafenib
panitumumab + encorafenib
20
HER2 inhibitor, EGFR inhibitor
trastuzumab + lapatinib
21
Folate analog, Thymidylate synthase inhibitor
5-fluorouracil + leucovorin calcium
22
VEGF-A inhibitor, VEGF-B inhibitor, PIGF inhibitor
ziv-aflibercept IV
23
TrkB receptor inhibitor, TrkC kinase inhibitor, ROS1 inhibitor, TrkA receptor inhibitor, ALK inhibitor, JAK2 inhibitor, TNK2 inhibitor
entrectinib
24
Thymidylate synthase inhibitor, Topoisomerase I inhibitor
capecitabine + irinotecan
25
Topoisomerase II inhibitor, DNA cross linking agent
idarubicin hydrochloride
doxorubicin hydrochloride
26
Topoisomerase II inhibitor
mitoxantrone
teniposide
epirubicin
27
Topoisomerase II inhibitor, DNA intercalator
daunorubicin
28
PIM inhibitor
AZD1208
No biomarker
KRAS G12C
KRAS wild-type
KRAS mutation
HER-2 amplification + RAS wild-type + BRAF wild-type
BRAF V600
RAS wild-type + BRAF wild-type
BRAF wild-type
BRAF mutation
NRAS wild-type
NRAS mutation
HER-2 amplification
MSI-H/dMMR
NTRK1 fusion
MSH2 deletion + MSH6 deletion
NTRK3 fusion
NTRK2 fusion
RET fusion
UGT1A1*1*1
PD-L1 expression
TMB-H
AFP elevation
EZH2 underexpression
RUNX3 overexpression
PTGS2 expression
CD177 expression
MLH1 deletion+ PMS2 deletion
MSH2 mutation
MSH6 mutation
KRAS mutation + ATM mutation
RAS mutation
TACC3 expression
TOP2A overexpression
PAI1 expression
TOP2A amplification